Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Keith W PratzMohamad CherryJessica K AltmanBrenda W CooperNikolai A PodoltsevJose Carlos CruzTara L LinGary J SchillerJoseph G JurcicAdam AschRuishan WuJason E HillStanley C GillAngela J JamesElizabeth Shima RichNahla HasabouAlexander E PerlMark J LevisPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
-mutant AML. The data herein provide an important framework for the design of randomized trials comparing gilteritinib with other FLT3 inhibitors.